Recombinant Zoster Vaccine (RZV) is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study.
Aakash DesaiJana G HashashGursimran S KochharMary S HayneyFreddy CalderaFrancis A FarrayePublished in: Journal of Crohn's & colitis (2024)
RZV is associated with a lower long-term risk of HZ in patients ≥50 years old with IBD. Given the widespread availability and safety of RZV, more effective vaccination strategies are needed to improve RZV utilization in this high-risk population.